健民集团(600976) - 2015 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders decreased by 7.76% to CNY 25,515,625.55 year-on-year[5] - Operating revenue decreased by 1.23% to CNY 461,103,761.61 compared to the same period last year[5] - Basic earnings per share decreased by 5.56% to CNY 0.17[5] - Total operating revenue for Q1 2015 was CNY 461,103,761.61, a decrease of 1.53% from CNY 466,824,063.25 in the same period last year[23] - Net profit for Q1 2015 was CNY 26,792,264.99, a decline of 6.5% compared to CNY 28,665,668.68 in Q1 2014[25] - Earnings per share for Q1 2015 were CNY 0.17, down from CNY 0.18 in the same quarter last year[25] - Investment income for Q1 2015 was CNY 7,693,586.66, a decrease of 14.2% from CNY 8,958,273.79 in Q1 2014[24] Assets and Liabilities - Total assets increased by 6.49% to CNY 1,647,190,025.90 compared to the end of the previous year[5] - The company's current assets totaled CNY 1,289,356,757.95, up from CNY 1,185,730,176.15, indicating an increase of about 8.7%[15] - The total liabilities of the company were CNY 618,372,615.06, compared to CNY 544,793,072.16 at the beginning of the year, which is an increase of about 13.5%[17] - Total liabilities as of Q1 2015 amounted to CNY 259,120,920.36, compared to CNY 222,554,408.52 in the previous year, reflecting a growth of 16.5%[21] - The company's equity attributable to shareholders rose to CNY 997,235,634.99 from CNY 971,720,009.44, reflecting an increase of approximately 2.6%[17] - Total equity increased to CNY 965,062,206.22, up from CNY 948,260,328.32, representing a growth of 1.5% year-over-year[21] Cash Flow - Net cash flow from operating activities increased by 12.52% to CNY 35,504,053.16 year-to-date[5] - Cash flow from operating activities increased to CNY 465,052,340.44, up 22.2% from CNY 380,523,730.83 in Q1 2014[28] - Operating cash inflow totaled CNY 920,561,124.35, an increase from CNY 442,290,810.41 in the previous period[29] - Net cash flow from operating activities was CNY 35,504,053.16, compared to CNY 31,552,918.27 in the prior period[29] - Cash and cash equivalents significantly rose to CNY 520,527,384.31 from CNY 175,164,077.31, marking an increase of approximately 197.5%[15] - Cash and cash equivalents at the end of the period reached CNY 520,527,384.31, up from CNY 211,446,133.53[30] - Total cash inflow from operating activities was CNY 453,845,337.53, compared to CNY 145,581,274.94 in the previous year[31] Shareholder Information - The total number of shareholders reached 11,625 at the end of the reporting period[9] - The largest shareholder, Huafang Pharmaceutical Technology Co., Ltd., holds 22.07% of the shares[9] Other Financial Indicators - The weighted average return on equity decreased by 0.39 percentage points to 2.59%[5] - Non-recurring gains and losses totaled CNY 5,087,725.70 for the reporting period[8] - The company has not reported any significant changes in accounting items or financial indicators[11] - The company reported a decrease in sales expenses to CNY 67,396,098.16, down 10.3% from CNY 75,458,559.66 in the previous year[24] - The company plans to focus on expanding its market presence and enhancing product development in the upcoming quarters[23]